Dainippon Sumitomo Licenses Japanese Rights to Two Redox-Directed Drugs from Edison Pharmaceuticals
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 4 (Table of Contents)
Published: 15 Apr-2013
DOI: 10.3833/pdr.v2013.i4.1922 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Dainippon Sumitomo Pharma (DSP) has licensed Japanese rights to develop and commercialise Edison Pharmaceuticals’ redox-directed drug candidates EPI-743 and EPI-589...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS